About Dr. Mandeep Singh Malhotra

Dr. Mandeep Singh Malhotra is a Senior Oncologist at CK Birla Hospital, New Delhi — a modern, JCI-standard hospital offering comprehensive cancer care. He is a highly experienced cancer specialist with expertise across multiple oncology disciplines, with particular focus on breast cancer, lung cancer, and gastrointestinal malignancies.

Dr. Mandeep Singh Malhotra — Cancer Specialist, CK Birla Hospital Delhi trained at top oncology institutes in India and brings a multidisciplinary approach to cancer care — working closely with surgical oncologists, radiation oncologists, and pathologists to develop individualised treatment plans for each patient. He is experienced in administering chemotherapy, targeted therapy, immunotherapy, and hormonal therapy for various cancer types.

CK Birla Hospital’s oncology department is equipped with advanced infusion facilities, port placement services, and dedicated day-care chemotherapy units — allowing most patients to receive treatment without lengthy hospital stays. This is particularly valuable for international patients from Kazakhstan and CIS countries who may need to manage their treatment in cycles with travel between sessions.

Conditions Treated

Consult Dr. Mandeep Singh Malhotra, Oncologist at CK Birla Hospital Delhi, who specialises in the diagnosis and treatment of:

• Breast Cancer — all stages, including triple-negative and HER2-positive
• Lung Cancer — NSCLC and SCLC, targeted therapy based on mutation profiling
• Colorectal and Gastrointestinal Cancers
• Cervical and Gynaecological Cancers
• Head and Neck Cancers
• Lymphoma — Hodgkin and Non-Hodgkin
• Chemotherapy administration — all major regimens
• Targeted Therapy — EGFR, HER2, ALK, PD-L1 inhibitors
• Immunotherapy — Pembrolizumab, Nivolumab, Atezolizumab
• Cancer Pain Management and Palliative Oncology

Why Kazakhstan & CIS Patients Choose Dr. Mandeep Singh Malhotra

For patients in Kazakhstan and CIS countries, access to advanced cancer treatments like targeted therapy and immunotherapy may be limited by availability, cost, or waiting times. In India, these treatments are available immediately at CK Birla Hospital through Dr. Mandeep Singh Malhotra, at costs 60 to 70 per cent lower than in Europe.

Chemotherapy cost in India: $250 to $600 per cycle depending on regimen. In Kazakhstan private hospitals: $800 to $1,500 per cycle. Targeted therapy agents like Trastuzumab, Erlotinib, and Pembrolizumab are available at significantly lower prices in India due to generic manufacturing. A full 6-cycle chemotherapy protocol in India costs $1,500 to $3,500 compared to $6,000 to $10,000 in Kazakhstan.

Experience Overview

Dr. Mandeep Singh Malhotra, Senior Oncologist, CK Birla Hospital brings over 20 years of experience in cancer surgery, with international exposure and expertise in complex reconstructions.

Total Experience: 20+ Years

 Work Experience Highlights:

• AIIMS, New Delhi
• Fortis Healthcare, Delhi
• Artemis Hospital, Delhi
• LNJP Hospital, Delhi
• Narayana Hospital, Bangalore
• Amrita Institute of Medical Sciences, Kochi
• Broomfield Hospital, Chelmsford, UK
• University of Pennsylvania (UPENN), USA
• NCC, Singapore

Professional Memberships

Dr. Mandeep Singh Malhotra is recognized globally for his clinical innovations and academic contributions in surgical oncology.

 Awards:

• Young Scientist Award – For contributions to surgical oncology and research

 Special Interests:

• Oncoplastic breast surgery with reconstruction
• Prophylactic mastectomy for BRCA-positive patients
• Robotic and endoscopic surgery for head & neck cancers
• Facial reconstruction post-cancer or trauma
• Precision oncology with integrative medicine

 Memberships & Academic Contributions:

• Speaker at international oncology conferences
• Contributor to reputed national and international medical journals
• Founder of the “Art of Healing Cancer” platform combining genetic mapping with traditional healing practices

Languages Spoken

Dr. Mandeep Singh Malhotra communicates effectively with international patients in the following languages:

• English
• Hindi

Frequently Asked Questions

Q: Can patients from Kazakhstan travel between chemotherapy cycles?

A: Yes, for most chemotherapy regimens. Cycles are typically 21 or 28 days apart. Between cycles, patients can travel back to Kazakhstan to be with their families, returning to India for the next cycle. Dr. Malhotra’s team provides a detailed cycle schedule in advance to allow for travel planning.

Q: How much does immunotherapy cost in India compared to Kazakhstan?

A: Pembrolizumab (Keytruda) — one of the most widely used immunotherapy agents — costs approximately $700 to $1,500 per cycle in India, compared to $3,000 to $5,000 per cycle in Kazakhstan or Turkey. Over a 6-cycle course, this represents a saving of $14,000 to $24,000 USD.

Q: Is targeted therapy available for lung cancer in India?

A: Yes. CK Birla Hospital offers comprehensive molecular profiling of lung tumours — including EGFR, ALK, ROS1, KRAS, and PD-L1 testing — enabling Dr. Malhotra to prescribe the most effective targeted therapy for each patient’s specific mutation profile.

Q: Can I get a second cancer opinion from Dr. Malhotra before starting treatment?

A: Absolutely. Second opinions in oncology are strongly encouraged. Send your biopsy report, PET/CT scan, previous treatment history, and blood results to MediKaya Healthcare. We will provide Dr. Malhotra’s review within 48 hours — free of charge, with no obligation to travel.

Q: What support is available for cancer patients from Kazakhstan during treatment in India?

A: MediKaya Healthcare provides a comprehensive international patient support package: airport pick-up, accommodation near CK Birla Hospital, Russian-speaking coordinator available throughout, regular family updates, and post-treatment follow-up coordination with your local oncologist in Kazakhstan.